ALAN M GEWIRTZ
Medical Practice in Philadelphia, PA

5427916, Jun 27, 1995

Aug 10, 1994

8/288151

Alan M. Gewirtz - Philadelphia PA
Bruno Calabretta - Philadelphia PA

Temple University of the Commonwealth System of Higher Education - Philadelphia PA

C12Q 168, C07H 2102, A61K 4300, A61K 4900

435 6

The effectiveness of selected antineoplastic agents may be determined in individual patients by comparing the level of expression of one or more selected growth-regulated genes in neoplastic cells taken from the patient before and shortly after the initiation of therapy. A decrement in expression is prognostic of eventual remission, while a lack of decrement indicates that remission is unlikely. The test may also be accomplished by comparing the level of expression of growth-regulated genes in neoplastic cells in culture before and after incubation of the cells with the selected antineoplastic agents.

5098890, Mar 24, 1992

Oct 27, 1989

7/427659

Alan M. Gewirtz - Philadelphia PA
Bruno Calabretta - Philadelphia PA

Temple University-of the Commonwealth System of Higher Education - Philadelphia PA

A61K 3170, C07H 2100

514 44

Oligonucleotides are provided having a nucleotide sequence complementary to at least a portion of the mRNA transcript of the human c-myb gene. These "antisense" oligonucleotides are hybridizable to the c-myb mRNA transcript. Such oligonucleotides are useful in treating hematologic neoplasms and in inducing immunosuppression. They are particularly useful as bone marrow purging agents.

5989849, Nov 23, 1999

Jun 5, 1995

8/461286

Alan M. Gewirtz - Philadelphia PA
Bruno Calabretta - Philadelphia PA

Temple University of the Commonwealth System of Higher Education - Philadephia PA

C12Q 102, C12Q 168, C12N 500, A61K 4800

435 29

Oligonucleotides are provided having a nucleotide sequence complementary to at least a portion of the mRNA transcript of the human c-kit gene. These "antisense" oligonucleotides are hybridizable to the c-kit mRNA transcript. Such oligonucleotides are useful in selectively inhibiting proliferation of erythroid cells, particularly in disorders characterized by an elevated hematocrit due to over-production of erythrocytes. The antisense oligomers also have activity agent hematologic neoplastic cells and are therefore suitable as bone marrow purging agents.

5612212, Mar 18, 1997

Nov 12, 1993

8/152634

Alan M. Gewirtz - Philadelphia PA

The University of Pennsylvania - Philadelphia PA

C12N 510, C12N 1585, C07H 2100, C12Q 168

4351723

Antisense oligonucleotides specific for the vav proto-oncogene inhibit the proliferation of malignant, but not normal, myeloid cells. The oligonucleotides are therefore useful in the treatment of leukemias, in particular, as bone marrow purging agents. The vav antisense oligonucleotides also selectively inhibit the formation of erythroid cell colonies without effect on megakaryocyte and granulocyte/macrophage colony formation. The oligonucleotides are therefore useful in treating disorders characterized by an elevated hematocrit due to overproduction of erythrocytes.

5472944, Dec 5, 1995

Dec 27, 1993

8/173264

Alan M. Gewirtz - Philadelphia PA
Mortimer Poncz - Wynnewood PA

The University of Pennsylvania - Philadelphia PA
Children's Hospital of Philadelphia - Philadelphia PA

A61K 3800, C07K 500, C07K 700, A01N 3718

514 12

Neutrophil activating peptide-2 or analog thereof is administered to a mammal to achieve therapeutic reduction of the number of circulating platelets. The peptide is useful in treating essential thrombocythemia and reactive thrombocytosis.

5618709, Apr 8, 1997

Jan 14, 1994

8/183211

Alan M. Gewirtz - Philadelphia PA
Donald Small - Baltimore MD
Curt I. Civin - Baltimore MD

University of Pennsylvania - Philadelphia PA
The Johns Hopkins University - Baltimore MD

C12N 1500, C07H 2104

4351723

Oligonucleotides are provided having a nucleotide sequence complementary to at least a portion of the mRNA transcript of the STK-1 gene. These "antisense" oligonucleotides are hybridizable to the STK-1 mRNA transcript. Such oligonucleotides are useful in treating neoplastic diseases characterized by activation of STK-1 gene expression. The oligonucleotides are also useful as bone marrow purging agents in the treatment of leukemia and metastasized neoplasms.

5306709, Apr 26, 1994

Nov 15, 1991

7/792988

Alan M. Gewirtz - Philadelphia PA

The University of Pennsylvania - Philadelphia PA

A61K 3702

514 12

Macrophage inflammatory protein-1 or -2, or analog thereof, is administered to a mammal to achieve therapeutic reduction of the number of circulating platelets. The proteins are useful in treating essential thrombocythemia and reactive thrombocytosis.

5185323, Feb 9, 1993

Mar 31, 1988

7/175552

Alan M. Gewirtz - Philadelphia PA

Temple University - Philadelphia PA

C07K 1506

514 12

Antimaturation factor (platelet factor 4 or active peptide segments thereof) is employed in the clinical treatment of coagulation disorders as an anticoagulant operating via an autoregulator mechanism for selectively suppressing megakaryocytopoiesis. Exposure of immature megakaryocytes to antimaturation factor reversibly inhibits cell maturation and, accordingly, functions characteristic of the mature cell, including platelet production and expression of genes coding for platelet coagulation factors, are reversibly suppressed.